🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

24 recruiting trials

for Hemophilia A and B

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B NCT06379789Phase 1, Phase 252 sites📍 Phoenix📍 Los Angeles📍 Los Angeles Regeneron Pharmaceuticals · Tests: REGV131, LNP1265 Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old NCT05709288Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BBM-H901 Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Blood sample A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B NCT05611801Phase 363 sites📍 Salt Lake City📍 Mendoza📍 Parkville Pfizer · Tests: marstacimab ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders NCT04398628n/a76 sites📍 Phoenix📍 Little Rock📍 Los Angeles American Thrombosis and Hemostasis Network World Bleeding Disorders Registry NCT03327779n/a1 site📍 Montreal World Federation of Hemophilia German Pediatric Hemophilia Research Database NCT02912143n/a1 site📍 Frankfurt am Main Goethe University · Tests: documentation only A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B NCT07285460Phase 341 sites📍 Los Angeles📍 Los Angeles📍 Orange Sanofi · Tests: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) NCT06349473Phase 110 sites📍 Glendale📍 Los Angeles📍 Chicago Equilibra Bioscience LLC · Tests: SR604, Placebo ATHNdataset Registry NCT06820515n/a1 site📍 Hickory American Thrombosis and Hemostasis Network Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis NCT07867821NA1 site📍 Milan Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Tests: Surgery Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors NCT05145127Phase 378 sites📍 Iowa City📍 New Hyde Park📍 Philadelphia Pfizer · Tests: PF-06741086 The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. NCT05630651NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: ZS801 Synovial Proliferation on Routine Ultrasound: Active or Inactive? NCT06809972n/a1 site📍 Utrecht Van Creveldkliniek · Tests: Ultrasound imaging An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency NCT07644832Phase 1, Phase 29 sites📍 Changsha📍 Hefei📍 Jinan Shanghai RAAS Blood Products Co., Ltd. · Tests: SR604, SR604, SR604 Safety of KN057 Prophylaxis in Patients With Haemophilia A or B NCT07545395Phase 31 site📍 Tianjin Suzhou Alphamab Co., Ltd. · Tests: KN057 SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors NCT04647227Phase 421 sites📍 Phoenix📍 Little Rock📍 Los Angeles American Thrombosis and Hemostasis Network · Tests: coagulation factor VIIa [recombinant]-jncw National Longitudinal Cohort of Hematological Diseases NCT04645199n/a1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China Longitudinal Cohort of Thrombosis and Hemostasis Diseases NCT06727669n/a5 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients NCT05641610Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: ZS801 Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively NCT05568719Phase 339 sites📍 Rancho Cordova📍 Sacramento📍 Sacramento Pfizer · Tests: Testing of hepatic AAV Vector integration Liver Biopsy In Haemophilia Gene Therapy NCT04817462NA1 site📍 London University College, London · Tests: Liver biopsy The European Paediatric Network for Haemophilia Management ( PedNet Registry) NCT02979119n/a39 sites📍 Graz📍 Vienna📍 Leuven PedNet Haemophilia Research Foundation SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis NCT04563520Phase 32 sites📍 Atlanta📍 Atlanta Emory University · Tests: Emicizumab, FEIBA, rFVIIa
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy